for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zynerba Pharmaceuticals Inc

ZYNE.OQ

Latest Trade

4.18USD

Change

-0.04(-0.95%)

Volume

67,996

Today's Range

4.11

 - 

4.22

52 Week Range

2.55

 - 

12.51

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.22
Open
4.16
Volume
67,996
3M AVG Volume
39.03
Today's High
4.22
Today's Low
4.11
52 Week High
12.51
52 Week Low
2.55
Shares Out (MIL)
24.95
Market Cap (MIL)
105.29
Forward P/E
-2.34
Dividend (Yield %)
--

Next Event

Zynerba Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X

Zynerba Pharmaceuticals Reports First Quarter 2020 Results

Zynerba Pharmaceuticals Announces Achievement Of Patient Screening Target For Pivotal Trial Of Zygel™ In Fragile X Syndrome

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Industry

Biotechnology & Drugs

Contact Info

80 W. Lancaster Avenue, Suite 300

DEVON, PA

19333

United States

+1.484.5817505

http://zynerba.com/

Executive Leadership

Armando Anido

Chairman of the Board, Chief Executive Officer

Terri B. Sebree

President

James E. Fickenscher

Chief Financial Officer, Vice President - Corporate Development

Suzanne M. Hanlon

Vice President, General Counsel, Secretary

Brian Rosenberger

Vice President - Commercial and Business Development

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.480

2018

-2.610

2019

-1.500

2020(E)

-1.800
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-53.83
Return on Equity (TTM)
-47.55

Latest News

Latest News

Zynerba's cannabis-based drug for rare genetic disorder fails study

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.

BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel

* ZYNERBA PHARMACEUTICALS ANNOUNCES TOP LINE RESULTS FROM PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ (CBD GEL) IN FRAGILE X SYNDROME

Zynerba's cannabis-based drug for rare genetic disorder fails study

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary goals of a pivotal trial in patients with a neurological disorder called Fragile X syndrome.

BRIEF-Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE RESULTS FROM EXPLORATORY OPEN LABEL PHASE 2 BRIGHT TRIAL OF ZYGEL IN AUTISM SPECTRUM DISORDER

BRIEF-Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X

* ZYNERBA PHARMACEUTICALS ANNOUNCES NEW TWO-YEAR DATA FROM OPEN LABEL EXTENSION OF THE PHASE 2 FAB-C TRIAL IN PATIENTS WITH FRAGILE X AT 2020 AMERICAN ACADEMY OF NEUROLOGY (AAN) SCIENCE HIGHLIGHTS VIRTUAL SESSION

BRIEF-Zynerba Pharmaceuticals Reports First Quarter 2020 Results

* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome

* ZYNERBA PHARMACEUTICALS ANNOUNCES THE COMPLETION OF ENROLLMENT IN THE PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME

BRIEF-Zynerba Pharmaceuticals Reports Q1 Loss Of $0.91 Per Share

* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study

* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2

BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors

* ZYNERBA PHARMACEUTICALS APPOINTS JOHN P. BUTLER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)

* ZYNERBA PHARMACEUTICALS INITIATES OPEN-LABEL PHASE 2 TRIAL OF ZYN002 IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE)

BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60

* ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING

BRIEF-Zynerba Pharmaceuticals reports Q3 loss per share of $0.63

* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights

Zynerba's stock on a high as cannabis-based drug succeeds in trial

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-derived gel to treat genetic disorder Fragile X syndrome succeeded in significantly reducing symptoms such as anxiety in a mid-stage study.

BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study

* Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study in children with Fragile X syndrome

Zynerba's cannabis-based gel succeeds in mid-stage study

Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel succeeded in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities.

BRIEF-Zynerba Pharmaceuticals announces results from phase 2 STOP clinical trial

* Zynerba Pharmaceuticals announces that results from phase 2 stop trial support continued development of ZYN002 in osteoarthritis

Zynerba shares plunge as cannabis-based epilepsy gel fails study

Zynerba Pharmaceuticals Inc's stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up